The Scientist

» drug development, disease/medicine and culture

Most Recent

The National Institutes of Health is hosting a two-day conference on how the virus affects infants and children. The take-home message so far: microcephaly is but one of many potential problems for Zika-exposed fetuses.

0 Comments

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.

0 Comments

image: Neonatal Gut Bacteria Might Promote Asthma

Neonatal Gut Bacteria Might Promote Asthma

By | September 12, 2016

Byproducts of gut microbes in some 1-month–old babies trigger inflammation that is linked to later asthma development, researchers find.

0 Comments

image: This is Your Brain on Art

This is Your Brain on Art

By | September 1, 2016

Nobel Laureate Eric Kandel talks about how our brains perceive and understand works of art.

1 Comment

In Chapter 13, “Why Is Reductionism Successful in Art?” author Eric Kandel explores what about abstract art challenges the human brain.

1 Comment

image: Designing In Vitro Models of the Blood-Brain Barrier

Designing In Vitro Models of the Blood-Brain Barrier

By | September 1, 2016

Choosing the right model, be it 3-D or 2-D, requires wading through varied cell sources, cell types, and cell culture conditions.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech